Back
Lyra Therapeutics, Inc. 10K Form
Sell
23
LYRA
Lyra Therapeutics, Inc.
Last Price:
$3.60
Seasonality Move:
3.74%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive LYRA News And Ratings
See the #1 stock for the next 7 days that we like better than LYRA
LYRA Financial Statistics
Sales & Book Value
| Annual Sales: | $1.5M |
|---|---|
| Cash Flow: | $-7.4M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $-2.63 |
| Price / Book: | 3.12 |
Profitability
| EPS (TTM): | -17.40850 |
|---|---|
| Net Income (TTM): | $-32.9M |
| Gross Margin: | $1.1M |
| Return on Equity: | -493.53% |
| Return on Assets: | -55.34% |
Lyra Therapeutics, Inc. Earnings Forecast
Key Lyra Therapeutics, Inc. Financial Ratios
-
The Gross Profit Margin over the past 7 years for LYRA is 69.30%.
-
The Selling, General & Administrative Expenses for LYRA have been equal to 1,206.06% of Gross Profit Margin.
-
The Research & Development expenses have been 2,822.36% of Revenue.
-
The Net Earning history of LYRA is -6,090.94% of Total Revenues.
-
Per Share Earnings over the last 7 years have been positive in 2 years.
Lyra Therapeutics, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Pharmaceuticals |
| Sector: | Health Care |
| Current Symbol: | LYRA |
| CUSIP: | 55234L |
| Website: | lyratherapeutics.com |
Debt
| Debt-to-Equity Ratio: | -7.25 |
|---|---|
| Current Ratio: | 2.43 |
| Quick Ratio: | 2.33 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
LYRA Technical Analysis vs Fundamental Analysis
Sell
23
Lyra Therapeutics, Inc. (LYRA)
is a Sell
Is Lyra Therapeutics, Inc. a Buy or a Sell?
-
Lyra Therapeutics, Inc. stock is rated a SellThe current Lyra Therapeutics, Inc. [LYRA] share price is $3.64. The Score for LYRA is 23, which is 54% below its historic median score of 50, and infers higher risk than normal.